Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by HarveyTwofaceon Apr 02, 2018 7:41pm
66 Views
Post# 27817694

RE:Thoughts on Celebrex/Cardiovascular issues

RE:Thoughts on Celebrex/Cardiovascular issuesHi,

Google this:

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis?

https://www.google.se/search?q=Do+selective+cyclo-oxygenase-2+inhibitors+and+traditional+non-steroidal+antiinflammatory+drugs+increase+the+risk+of+atherothrombosis%3F&oq=Do++selective+cyclo-oxygenase-2+inhibitors+and+traditional+non-steroidal+antiinflammatory++drugs+increase+the+risk+of+atherothrombosis%3F&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8


Quote from page 3 : "We chose naproxen as the NSAID to use as the base drug because it is the only marketed NSAID that has not been associated with significant and serious cardiovascular adverse events [36]. Indeed, concerns about these cardiovascular events have led to several large physician’s groups (e.g., American Heart Association, American College of Gastroenterology) to recommend use of naproxen, or of a selective COX-2 inhibitor plus low-dose aspirin"

https://www.antibethera.com/wordpress/wp-content/uploads/2015/12/Gemici-et-al-Nitric-Oxide-Nov-2014.pdf



Bullboard Posts